Actuate Therapeutics develops elraglusib, a GSK-3 inhibitor that targets multiple molecular pathways to slow, stop, or shrink tumors in patients with hard-to-treat cancers. This approach aims to enhance anti-tumor immunity while minimizing adverse effects associated with conventional therapies.

Immusoft utilizes Immune System Programming (ISP™) to reprogram a patient's B cells into plasma cells that produce therapeutic proteins, effectively creating personalized biofactories for treatment. This technology addresses the need for sustained delivery of gene-encoded medicines for rare diseases, offering long-term therapeutic benefits from the patient's own cells.

Lantern Pharma develops precision oncology therapies using artificial intelligence, machine learning, and genomics to enhance the efficiency and accuracy of drug discovery and development. The company addresses the high costs and lengthy timelines associated with oncology drug development by utilizing a data-driven platform that analyzes over 100 billion data points to identify effective treatment candidates.

Renibus Therapeutics is developing RBT-1, a first-in-class intravenous drug designed to reduce postoperative complications in patients undergoing elective cardiac and valve surgeries. The company also offers Veverimer, an oral hydrochloric acid binder targeting orphan diseases with unmet medical needs, aiming to improve patient outcomes and protect against organ damage associated with cardio, renal, and metabolic diseases.

Stream Biomedical develops neuroprotective and neuroreparative therapies using targeted drug delivery systems to enhance neuronal survival and recovery. The company addresses the critical need for effective treatments in neurodegenerative diseases and brain injuries, aiming to improve patient outcomes and quality of life.

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.